Fintel reports that on November 11, 2025, Wells Fargo maintained coverage of MannKind (NasdaqGM:MNKD) with a Overweight ...

This article first appeared on GuruFocus. MannKind Corp (NASDAQ:MNKD) is set to release its Q3 2025 earnings on Nov 5, 2025.

MannKind (MNKD) stock jumps after Q3 2025 results beat forecasts, driven by Afrezza growth and strong cash position. Read more here.

MannKind Corporation ( MNKD) saw a stock decline after the announcement that it would discontinue its trial testing MNKD-101, a nebulized form of clofazimine intended for treating refractory ...

In addition to Wells Fargo, MannKind also received a Buy from RBC Capital’s Douglas Miehm in a report issued on November 10. However, on November 6, TR | OpenAI – 4o reiterated a Hold rating on ...

MannKind (MNKD) delivered earnings and revenue surprises of +200.00% and +1.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

The company said it is discontinuing the phase 3 ICoN-1 clinical trial evaluating MNKD-101 which aimed to treat refractory nontuberculous mycobacterial lung disease, a persistent, hard-to-treat lung ...

We can see that MannKind does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the ...

The Danbury, Connecticut-based company said it had profit of 3 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

Conference call today at 9:00 am ETQ3 2025 revenues of $82.1M, +17% v. Q3 2024YTD 2025 revenues of $237.0M, +14% v. YTD 2024Completed acquisition of scPharmaceuticals on October 7, accelerating ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its third quarter 2025 financial results will be released ...

DANBURY, Conn. and BURLINGTON, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The ...